Use of lymphoplasmapheresis or plasmapheresis in the management of acute renal allograft rejection
β Scribed by Steven Kleinman; Marcus Nichols; Franklin Strauss; Dennis Goldfinger
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 285 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Several recent reports have documented the value of intensive plasmapheresis as an adjunct to standard immunosuppressive therapy for patients suffering acute renal allograft rejection. We have treated four rejection episodes in three patients with intensive plasmapheresis and two rejection episodes in two additional patients with intensive lymphoplasmapheresis. Five of six rejection episodes were reversed, and four of the five patients treated have retained functioning grafts for followβup periods ranging from 4 months to 3 years. Previous investigators have reported encouraging results using plasmapheresis, and we believe our experience supports the requirement for further controlled studies with this procedure. Moreover, we note that no previous work has been described with lymphoplasmapheresis and suggest that removal of lymphocytes, in addition to plasma, may further augment immunosuppression in the treatment of renal allograft rejection.
π SIMILAR VOLUMES
## Abstract The application of multiple immunosuppressive therapy for organ transplantation could enhance therapeutic efficacy, while minimizing the toxicity of individual drugs used in the regimen. In this study, the effect of the combined therapy of vincristine (VCR) with tacrolimus (FK506) or si
The effect of rapamycin (RAPA) and cyclosporine A (CsA) monotherapy and combination therapy was examined in prevention of kidney allograft rejection in the mouse. Both drugs were administered orally for up to 14 days in BALB/c (H-2 d ) to C57BL/6 (H-2 b ) mice strong combination. Six groups were tre